Gene therapy injection tested to halt rapid blindness

NCT ID NCT02652767

Summary

This study tested whether a single gene therapy injection (called GS010) into the eye could improve or preserve vision in people with a rare, rapidly progressing form of inherited blindness (LHON). It involved 39 participants who had started losing vision within the last 6 months. The trial compared the real injection to a sham (pretend) procedure to see if the treatment was effective.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPTIC, ATROPHY, HEREDITARY, LEBER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre National Hospitalier d'Ophtalmologie des Quinze-VingtCentre National Hospitalier d'Ophtalmologie des Quinze-Vingt

    Paris, Paris, France

  • Department of Neurology, University of Munich, Friedrich-Baur-Institute

    Munich, 80336, Germany

  • Department of Ophthalmology, Emory University School of Medicine

    Atlanta, Georgia, 30322, United States

  • Doheny Eye Center, University of California, Los Angeles

    Los Angeles, California, 91105, United States

  • IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Ospedale Bellaria

    Bologna, Bologna, Italy

  • Moorfields Eye Hospital NHS Foundation Trust

    London, EC1V 2PD, United Kingdom

  • Neuro Ophthalmologic Associates, Wills Eye Hospital, Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

Conditions

Explore the condition pages connected to this study.